SANSAC Drug Patent Profile
✉ Email this page to a colleague
When do Sansac patents expire, and when can generic versions of Sansac launch?
Sansac is a drug marketed by Dow Pharm and is included in one NDA.
The generic ingredient in SANSAC is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sansac
A generic version of SANSAC was approved as erythromycin by TORRENT on July 6th, 2020.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SANSAC?
- What are the global sales for SANSAC?
- What is Average Wholesale Price for SANSAC?
Summary for SANSAC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 103 |
| Patent Applications: | 4,160 |
| DailyMed Link: | SANSAC at DailyMed |
US Patents and Regulatory Information for SANSAC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dow Pharm | SANSAC | erythromycin | SOLUTION;TOPICAL | 062522-001 | Jan 24, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
